Regeneron Pharmaceuticals has announced a monumental research collaboration with Parabilis Medicines, a deal valued at an impressive $2.32 billion. This…
Read More
Arna Pharma and Slate Run Pharmaceuticals Forge Strategic Joint Venture to Accelerate Pharmaceutical Product Commercialization in the US Market
Arna Pharma and Slate Run Pharmaceuticals have finalized a significant joint venture (JV), establishing a new specialized pharmaceutical entity poised…
Read More
Angelini Pharma Acquires Catalyst Pharmaceuticals for $4.1 Billion to Bolster Rare Disease and Brain Health Portfolio
Angelini Pharma, a prominent player in the pharmaceutical sector, has announced a definitive agreement to acquire Catalyst Pharmaceuticals for an…
Read More
Merck & Co. Acquires Terns Pharmaceuticals, Bolstering Chronic Myeloid Leukemia Pipeline with FDA Breakthrough Designation for TERN-701
Merck & Co. (MSD) has successfully completed its acquisition of Terns Pharmaceuticals, a strategic move that significantly enhances MSD’s portfolio…
Read More
Madrigal Pharmaceuticals Secures Global Rights to Arrowhead’s siRNA Asset for MASH, Paving Way for Combination Therapy Exploration
Madrigal Pharmaceuticals has significantly bolstered its pipeline for metabolic dysfunction-associated steatohepatitis (MASH) by acquiring the global rights to Arrowhead Pharmaceuticals’…
Read More
Arrowhead Pharmaceuticals Secures Australian TGA Approval for Redemplo, Offering Hope for Familial Chylomicronemia Syndrome Patients
The Australian Therapeutic Goods Administration (TGA) has granted approval for Arrowhead Pharmaceuticals’ Redemplo (plozasiran), a novel therapeutic agent designed to…
Read More
Chiesi Acquires KalVista Pharmaceuticals for $1.9 Billion, Bolstering Rare Disease Portfolio with On-Demand HAE Treatment
In a landmark move that marks the largest acquisition in its 90-year history, Italian pharmaceutical giant Chiesi has agreed to…
Read More
Teva Pharmaceuticals Acquires Emalex Biosciences for $700 Million to Bolster Neurology Pipeline and Drive Growth Strategy
Teva Pharmaceuticals is set to significantly expand its presence in the neuroscience market with the acquisition of Emalex Biosciences, a…
Read More
Apotex Acquires Cumberland Pharmaceuticals’ Branded Drug Portfolio for $100 Million, Ushering in New Era for Both Companies
Canadian pharmaceutical giant Apotex has announced a significant strategic acquisition, agreeing to purchase Cumberland Pharmaceuticals’ entire portfolio of branded commercial…
Read More
Enanta Pharmaceuticals Poised to Lead Emerging RSV Therapeutics Market as Zelicapavir Advances to Phase III
Enanta Pharmaceuticals is strategically positioned to capture a significant share of the largely undeveloped market for respiratory syncytial virus (RSV)…
Read MoreYOU MAY HAVE MISSED
